Please assess the completion status of the following clinical trial:

Trial Title: APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of 18 to 85 years of age (inclusive);~* Have a diagnosis of FAP~* Neuropathy Impairment Score requirement of 5-130~* Meet Karnofsky performance status requirements~* Have adequate complete blood counts and liver function tests~* Have adequate cardiac function~* Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)~Exclusion Criteria:~* Had a prior liver transplant or is planned to undergo liver transplant during the study period;~* Has untreated hypo- or hyperthyroidism;~* Has known human immunodeficiency virus (HIV) infection;~* Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;~* Recently received an investigational agent or device~* Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- patisiran (ALN-TTR02) (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).